Stryker price target raised to $315 from $288 at RBC Capital

RBC Capital analyst Shagun Singh raised the firm’s price target on Stryker to $315 from $288 and keeps an Outperform rating on the shares. The analyst cites the company’s revenue and earnings beat that was driven by "broad-based growth" but especially by Orthopedics. RBC further notes that Stryker expects its strong business momentum to continue throughout the rest of the year with a strong order book and a "super cycle" of new products.